{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:40:13Z","timestamp":1776742813690,"version":"3.51.2"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.clinthera.2014.10.009","type":"journal-article","created":{"date-parts":[[2014,11,16]],"date-time":"2014-11-16T18:32:10Z","timestamp":1416162730000},"page":"2072-2079","source":"Crossref","is-referenced-by-count":47,"title":["Do Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Cause Heart Failure?"],"prefix":"10.1016","volume":"36","clinical-trial-number":[{"clinical-trial-number":"nct00790205","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6411-626X","authenticated-orcid":false,"given":"Peter","family":"Clifton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2014.10.009_bib1","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.2337\/dc11-s229","article-title":"(DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors","volume":"34","author":"Dicker","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2014.10.009_bib2","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.10.009_bib3","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.10.009_bib4","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1056\/NEJMc1313880","article-title":"Alogliptin, and Cardiovascular Outcomes","volume":"370","author":"Scirica","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.10.009_bib5","unstructured":"Scirica BM, Braunwald E, Raz I, et al. for the SAVOR-TIMI 53 Steering Committee and Investigators Heart Failure, Saxagliptin and Diabetes Mellitus: Observations from the SAVOR - TIMI 53 Randomized Trial. http:\/\/circ.ahajournals.org\/content\/early\/2014\/09\/04\/CIRCULATIONAHA.114.010389. Accessed September 30, 2014"},{"issue":"5","key":"10.1016\/j.clinthera.2014.10.009_bib6","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1517\/14740338.2014.904284","article-title":"Gliptins - do they increase cardiovascular risk or benefit?","volume":"13","author":"Doggrell","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"10.1016\/j.clinthera.2014.10.009_bib7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3810\/pgm.2014.05.2756","article-title":"Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus","volume":"126","author":"Davidson","year":"2014","journal-title":"Postgrad Med"},{"key":"10.1016\/j.clinthera.2014.10.009_bib8","article-title":"Effects of incretin-based therapy in patients with heart failure and myocardial infarction","volume":"Feb 4","author":"Mikhail","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.clinthera.2014.10.009_bib9","article-title":"The Vildagliptin in Ventricular Dysfunction Diabetes (VIVIDD) trial","author":"McMurray","year":"2013","journal-title":"Presented at the Heart Failure Congress"},{"key":"10.1016\/j.clinthera.2014.10.009_bib10","article-title":"No Significant Difference in Risk of Heart Failure Hospitalization with Vildagliptin in Diabetic Patients with Systolic Chronic Heart Failure: VIVIDD","author":"Krum","year":"2014","journal-title":"Poster 28 at The American Diabetes Association Annual Scientific Meeting Chicago"},{"key":"10.1016\/j.clinthera.2014.10.009_bib11","article-title":"Safety of linagliptin in 8778 patients with type 2 diabetes mellitus: pooled analysis of 23 placebo-controlled randomised clinical trials","author":"Schernthaner","year":"2014","journal-title":"Poster 885 European Association for the Study of Diabetes Vienna"},{"key":"10.1016\/j.clinthera.2014.10.009_bib12","article-title":"Assessment of heart failure risk with vildagliptin in diabetic patients: pooled analysis of safety data from approximately 17,000 patients","author":"Evans","year":"2014","journal-title":"Poster 888 European Association for the Study of Diabetes Vienna"},{"issue":"7","key":"10.1016\/j.clinthera.2014.10.009_bib13","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.numecd.2014.01.017","article-title":"Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials","volume":"24","author":"Monami","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.clinthera.2014.10.009_bib14","article-title":"Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study","author":"Kim","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2014.10.009_bib15","unstructured":"Kannan S, Torricelli SM, Pantalone KM, et al. The Risk of Overall Mortality and Cardiovascular Events in Patients with Type 2 Diabetes on Dual Drug Therapy Including Metformin: A Large Database Study from Cleveland Clinic. Joint Meeting of the International Society of Endocrinology and the Endocrine Society: ICE\/ENDO 2014 June 21-24, 2014; Chicago, Illinois"},{"key":"10.1016\/j.clinthera.2014.10.009_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2014.04.005","article-title":"Sitagliptin Use in Patients With Diabetes and Heart Failure: A Population-Based Retrospective Cohort Study","author":"Weir","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.clinthera.2014.10.009_bib17","article-title":"Incretin-Based Drugs and the Risk of Congestive Heart Failure","author":"Yu","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2014.10.009_bib18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1475-2840-13-33","article-title":"Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials","volume":"13","author":"Iqbal","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clinthera.2014.10.009_bib19","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.cardfail.2006.08.211","article-title":"Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure","volume":"12","author":"Sokos","year":"2006","journal-title":"J Card Fail"},{"key":"10.1016\/j.clinthera.2014.10.009_bib20","doi-asserted-by":"crossref","first-page":"H2401","DOI":"10.1152\/ajpheart.00347.2005","article-title":"Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy","volume":"289","author":"Nikolaidis","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"10.1016\/j.clinthera.2014.10.009_bib21","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/CIRCINTERVENTIONS.110.960476","article-title":"A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans","volume":"4","author":"Read","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.clinthera.2014.10.009_bib22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.109.899377","article-title":"DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease","volume":"3","author":"Read","year":"2010","journal-title":"Circ Cardiovasc Imaging"},{"issue":"5","key":"10.1016\/j.clinthera.2014.10.009_bib23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/1755-5922.12005","article-title":"DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes","volume":"31","author":"Connelly","year":"2013","journal-title":"Cardiovasc Ther"},{"issue":"11","key":"10.1016\/j.clinthera.2014.10.009_bib24","doi-asserted-by":"crossref","first-page":"e27861","DOI":"10.1371\/journal.pone.0027861","article-title":"Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy","volume":"6","author":"Chaykovska","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2014.10.009_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1475-2840-10-85","article-title":"Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure","volume":"10","author":"Yin","year":"2011","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clinthera.2014.10.009_bib26","first-page":"03062","article-title":"Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus","volume":"114","author":"Ferdinand","year":"2014","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.clinthera.2014.10.009_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001986","article-title":"Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis","volume":"3","author":"Robinson","year":"2013","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.clinthera.2014.10.009_bib28","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/HYPERTENSIONAHA.110.156554","article-title":"Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans","volume":"56","author":"Marney","year":"2010","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.clinthera.2014.10.009_bib29","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/hrt.2006.110239","article-title":"B-type natriuretic peptide infusions in acute myocardial infarction","volume":"94","author":"Hillock","year":"2008","journal-title":"Heart"},{"issue":"16","key":"10.1016\/j.clinthera.2014.10.009_bib30","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1136\/hrt.2008.153916","article-title":"JrLow-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study","volume":"95","author":"Chen","year":"2009","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.clinthera.2014.10.009_bib31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/eurjhf\/hfr146","article-title":"Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure","volume":"14","author":"Gomez","year":"2012","journal-title":"Eur J Heart Fail"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181400678X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181400678X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T15:54:12Z","timestamp":1538063652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929181400678X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S014929181400678X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.10.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}